8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 23, 2026·SEC
Corvus Pharmaceuticals, Inc.(CRVS)Earnings, Financials & Key Ratios
CRVS•NASDAQ
Price updated Jun 19, 2026
AboutCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.Show more
- Revenue$0
- EBITDA-$43M-56.1%
- Net Income-$15M+75.5%
- EPS (Diluted)-0.53+48.0%
- ROE-32.6%+81.4%
CRVS Key Insights
Corvus Pharmaceuticals, Inc. (CRVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 20.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 30.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 15.5x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRVS Price & Volume
Corvus Pharmaceuticals, Inc. (CRVS) stock price & volume — 10-year historical chart
Loading chart...
CRVS Growth Metrics
Corvus Pharmaceuticals, Inc. (CRVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-6.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.88%
Return on Capital
10 Years-54.89%
5 Years-60.25%
3 Years-71.74%
Last Year-90.23%
CRVS Recent Earnings
Corvus Pharmaceuticals, Inc. (CRVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
—
$775,000
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.12+14.3%
$0.14
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.10+23.1%
$0.13
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.14-7.1% | — |
| Q2 2026 | Mar 12, 2026 | $0.15vs $0.14-7.1% | —vs $775,000 |
| Q4 2025 | Nov 4, 2025 | $0.12vs $0.14+14.3% | — |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.13+23.1% | — |
Based on last 12 quarters of dataView full earnings history →
CRVS Peer Comparison
Corvus Pharmaceuticals, Inc. (CRVS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 NKTX | 204.62M | 2.86 | -2.03 | -30.9% | 0.24 | |||
 ALEC | 194.29M | 1.75 | -1.26 | -79.07% | -6.81% | -295.17% | 1.18 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare CRVS vs Peers
Corvus Pharmaceuticals, Inc. (CRVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRVS Income Statement
Corvus Pharmaceuticals, Inc. (CRVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 842K | 847K | 0 | 0 | 0 | 0 | 0 | 0 | 105K | 55K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -842K▲ 0% | -847K▼ 0.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -105K▲ 0% | -55K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -41.75% | -0.59% | 100% | - | - | - | - | - | - | - |
Operating Expenses | 56.52M | 49.22M | 48.85M | 43.76M | 38.63M | 32.56M | 23.41M | 27.55M | 42.87M | 47.9M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 10.22M | 10.64M | 10.88M | 11.93M | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M | 10.48M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 46.3M | 38.59M | 37.98M | 31.83M | 29.11M | 24.47M | 16.53M | 19.39M | 33.72M | 37.44M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -105K | 0 |
Operating Income | -56.52M▲ 0% | -49.22M▲ 12.9% | -48.85M▲ 0.7% | -43.76M▲ 10.4% | -38.63M▲ 11.7% | -32.56M▲ 15.7% | -23.41M▲ 28.1% | -27.55M▼ 17.7% | -42.97M▼ 56.0% | -47.93M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -52.87% | 12.92% | 0.75% | 10.43% | 11.72% | 15.7% | 28.12% | -17.69% | -55.99% | - |
EBITDA | -55.68M | -48.38M | -48.11M | -43.13M | -38.17M | -32.2M | -23.26M | -27.46M | -42.87M | -47.81M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -53.05% | 13.12% | 0.55% | 10.36% | 11.5% | 15.65% | 27.77% | -18.09% | -56.09% | -53.58% |
D&A (Non-Cash Add-back) | 842K | 847K | 743K | 632K | 460K | 367K | 151K | 85K | 105K | 112K |
EBIT | -55.66M | -46.94M | -48.85M | -6M | -38.63M | -32.56M | -23.41M | -27.55M | -42.97M | -47.51M |
Net Interest Income | 0 | 0 | 0 | 0 | -15K | 654K | 1.58M | 1.82M | 2.5M | -2.31M |
Interest Income | 861K | 2.28M | 2.18M | 540K | 0 | 654K | 1.58M | 1.82M | 2.5M | -525K |
Interest Expense | 0 | 2.28M | 2.18M | 540K | 15K | 0 | 0 | 0 | 0 | 1.78M |
Other Income/Expense | 861K | 2.28M | 2.18M | 37.77M | -4.61M | -8.74M | -3.62M | -34.74M | 27.69M | 3.76M |
Pretax Income | -55.66M▲ 0% | -46.94M▲ 15.7% | -46.67M▲ 0.6% | -6M▲ 87.2% | -43.24M▼ 621.3% | -41.31M▲ 4.5% | -27.03M▲ 34.6% | -62.29M▼ 130.5% | -15.28M▲ 75.5% | -44.17M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -55.66M▲ 0% | -46.94M▲ 15.7% | -46.67M▲ 0.6% | -6M▲ 87.2% | -43.24M▼ 621.3% | -41.31M▲ 4.5% | -27.03M▲ 34.6% | -62.29M▼ 130.5% | -15.28M▲ 75.5% | -44.17M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -53.03% | 15.67% | 0.57% | 87.16% | -621.28% | 4.47% | 34.57% | -130.47% | 75.47% | -6.69% |
Net Income (Continuing) | -55.66M | -46.94M | -46.67M | -6M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M | -44.17M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.72▲ 0% | -1.71▲ 37.1% | -1.49▲ 12.9% | -0.20▲ 86.6% | -1.03▼ 415.0% | -0.89▲ 13.6% | -0.56▲ 36.8% | -1.02▼ 81.2% | -0.53▲ 48.0% | -0.49▲ 0% |
EPS Growth % | -15.25% | 37.13% | 12.87% | 86.58% | -415% | 13.59% | 36.76% | -81.24% | 48.04% | 43.88% |
EPS (Basic) | -2.72 | -1.71 | -1.49 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.19 | - |
Diluted Shares Outstanding | 20.49M | 27.51M | 29.35M | 29.48M | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M | 90M |
Basic Shares Outstanding | 20.49M | 27.51M | 29.35M | 29.48M | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M | 90M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CRVS Balance Sheet
Corvus Pharmaceuticals, Inc. (CRVS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 90.06M | 114.6M | 79.34M | 45.34M | 71.31M | 43.66M | 27.96M | 54.41M | 58.21M | 239.95M |
Cash & Short-Term Investments | 90.06M | 114.6M | 77.98M | 44.26M | 69.45M | 42.3M | 27.15M | 51.96M | 56.75M | 236.71M |
Cash Only | 90.06M | 114.6M | 5.15M | 16.45M | 63.46M | 13.16M | 12.62M | 8.74M | 4.58M | 40.1M |
Short-Term Investments | 0 | 0 | 72.83M | 27.8M | 5.99M | 29.14M | 14.53M | 43.22M | 52.17M | 196.61M |
Accounts Receivable | 132K | 337K | 329K | 0 | 539K | 633K | 63K | 216K | 374K | 43K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | -852K | -602K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 720K | 265K | 486K | 673K | 128K | 102K | 220K | 548K | 318K | 3.19M |
Total Non-Current Assets | 4.72M | 3.63M | 4.3M | 40.19M | 38.14M | 24.58M | 17.6M | 14.5M | 12.9M | 13.25M |
Property, Plant & Equipment | 2.67M | 2.18M | 3.79M | 2.55M | 3.64M | 2.57M | 1.39M | 1.33M | 1.06M | 1.03M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 37.23M | 34.27M | 21.88M | 16.12M | 12.54M | 10.99M | 44.81M |
Other Non-Current Assets | 2.05M | 1.46M | 513K | 414K | 236K | 129K | 89K | 632K | 855K | 1.72M |
Total Assets | 94.78M▲ 0% | 118.23M▲ 24.8% | 83.65M▼ 29.3% | 85.53M▲ 2.3% | 109.45M▲ 28.0% | 68.24M▼ 37.7% | 45.55M▼ 33.2% | 68.91M▲ 51.3% | 71.12M▲ 3.2% | 253.19M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -32.38% | 24.75% | -29.25% | 2.25% | 27.97% | -37.65% | -33.25% | 51.27% | 3.21% | 404.59% |
Total Current Liabilities | 9.94M | 7.9M | 10.22M | 12.15M | 9.69M | 10.75M | 6.87M | 35.4M | 9.38M | 12.11M |
Accounts Payable | 3.45M | 2M | 2.45M | 3.47M | 1.56M | 1.98M | 1.52M | 2.58M | 2.49M | 4.7M |
Days Payables Outstanding | 1.5K | 861 | - | - | - | - | - | - | 8.66K | 20.41K |
Short-Term Debt | 0 | 0 | 878K | 0 | 0 | 0 | 0 | 0 | 403K | 428K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.94M | 4.38M | 5.28M | 180K | 1.97M | 1.27M | 929K | 30.02M | 5.84M | 6.99M |
Current Ratio | 9.06x | 14.51x | 7.76x | 3.73x | 7.36x | 4.06x | 4.07x | 1.54x | 6.21x | 19.81x |
Quick Ratio | 9.15x | 14.59x | 7.76x | 3.73x | 7.36x | 4.06x | 4.07x | 1.54x | 6.21x | 19.81x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 971K | 869K | 2.31M | 1.23M | 2.6M | 1.37M | 0 | 937K | 534K | 406K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 406K |
Capital Lease Obligations | 0 | 0 | 2.31M | 1.23M | 2.6M | 1.37M | 0 | 937K | 534K | 1.89M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 971K | 869K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.94M | 7.9M | 12.54M | 13.38M | 12.29M | 12.13M | 6.87M | 36.34M | 9.91M | 12.52M |
Total Debt | 0 | 0 | 3.19M | 2.31M | 3.65M | 2.6M | 1.37M | 1.12M | 937K | 834K |
Net Debt | -90.06M | -114.6M | -1.97M | -14.14M | -59.81M | -10.56M | -11.25M | -7.62M | -3.64M | -39.27M |
Debt / Equity | - | - | 0.04x | 0.03x | 0.04x | 0.05x | 0.04x | 0.03x | 0.02x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.82x |
Interest Coverage | - | -20.56x | -22.39x | -11.10x | -2575.33x | - | - | - | - | -26.63x |
Total Equity | 84.83M▲ 0% | 110.34M▲ 30.1% | 71.11M▼ 35.6% | 72.15M▲ 1.5% | 97.16M▲ 34.7% | 56.12M▼ 42.2% | 38.68M▼ 31.1% | 32.57M▼ 15.8% | 61.2M▲ 87.9% | 240.68M▲ 0% |
Equity Growth % | -36.12% | 30.06% | -35.55% | 1.46% | 34.67% | -42.25% | -31.06% | -15.81% | 87.93% | 1010.85% |
Book Value per Share | 4.14 | 4.01 | 2.42 | 2.45 | 2.32 | 1.21 | 0.81 | 0.53 | 0.77 | 2.67 |
Total Shareholders' Equity | 84.83M | 110.34M | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M | 32.57M | 61.2M | 240.68M |
Common Stock | 2K | 3K | 3K | 3K | 5K | 5K | 5K | 7K | 7K | 8K |
Retained Earnings | -123.53M | -170.47M | -217.15M | -223.14M | -266.38M | -307.69M | -334.72M | -397.01M | -412.29M | -425.99M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -41K | -34K | 29K | 4K | 1.87M | -563K | -967K | -1.29M | -896K | -1.13M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRVS Cash Flow Statement
Corvus Pharmaceuticals, Inc. (CRVS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -46.21M | -40.99M | -37.32M | -34.78M | -36.72M | -27.02M | -23.93M | -25.42M | -32.8M | -34.91M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -65.89% | 11.3% | 8.95% | 6.81% | -5.57% | 26.4% | 11.43% | -6.22% | -29% | -90.86% |
Net Income | -55.66M | -46.94M | -46.67M | -6M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M | -44.17M |
Depreciation & Amortization | 842K | 847K | 743K | 632K | 460K | 367K | 151K | 85K | 105K | 112K |
Stock-Based Compensation | 6.23M | 7.13M | 7.35M | 5.75M | 4.23M | 2.69M | 2.15M | 3M | 5.33M | 6.73M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -195K | -608K | -644K | -37.07M | 5.07M | 9.81M | 4.39M | 35.43M | -26.53M | -1.06M |
Working Capital Changes | 2.58M | -1.42M | 1.9M | 1.91M | -3.24M | 1.41M | -3.59M | -1.65M | 3.58M | 3.48M |
Change in Receivables | 0 | 0 | 0 | 0 | -507K | -81K | 562K | -49K | 38K | 36K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.55M | -1.46M | 450K | 1.02M | -1.9M | 411K | -451K | 1.06M | -91K | 3.39M |
Cash from Investing | 84.83M | -30.19M | 3.25M | 44.77M | 21.56M | -23.28M | 15.54M | -27.48M | -7.8M | -156.88M |
Capital Expenditures | -266K | -355K | -25K | -76K | -5K | -269K | -34K | 0 | -174K | -229K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | -44.84K | -21.57K | 22K | 0 | 5K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 85.09M | -29.84M | 0 | 44.84K | 21.57K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.44M | 65.27M | 24K | 1.31M | 62.16M | 0 | 7.86M | 49.03M | 36.43M | 226.9M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 711K | 64.88M | 0 | 1.22M | 60.94M | 0 | 7.84M | 16.41M | 36.43M | 226.9M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 731K | 393K | 24K | 88K | 1.22M | 0 | 12K | 32.62M | 0 | 0 |
Net Change in Cash | 40.06M▲ 0% | -5.91M▼ 114.8% | -34.04M▼ 476.0% | 11.3M▲ 133.2% | 47M▲ 315.9% | -50.3M▼ 207.0% | -539K▲ 98.9% | -3.88M▼ 619.9% | -4.16M▼ 7.3% | 35.1M▲ 0% |
Free Cash Flow | -46.48M▲ 0% | -41.34M▲ 11.0% | -37.35M▲ 9.7% | -34.85M▲ 6.7% | -36.72M▼ 5.4% | -27.29M▲ 25.7% | -23.97M▲ 12.2% | -25.42M▼ 6.1% | -32.97M▼ 29.7% | -35.14M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -54.64% | 11.05% | 9.67% | 6.67% | -5.35% | 25.68% | 12.18% | -6.07% | -29.68% | -23% |
FCF per Share | -2.27 | -1.50 | -1.27 | -1.18 | -0.88 | -0.59 | -0.50 | -0.42 | -0.41 | -0.39 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.87x | 0.80x | 5.80x | 0.85x | 0.65x | 0.89x | 0.41x | 2.15x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRVS Key Ratios
Corvus Pharmaceuticals, Inc. (CRVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -51.15% | -48.1% | -51.44% | -8.37% | -51.08% | -53.9% | -57.02% | -174.85% | -32.6% | -38.92% |
Return on Invested Capital (ROIC) | - | - | -112.94% | -51.62% | -60.77% | -58.92% | -48.1% | -78.88% | -78.11% | -36.35% |
Debt / Equity | - | - | 0.04x | 0.03x | 0.04x | 0.05x | 0.04x | 0.03x | 0.02x | 0.00x |
Interest Coverage | - | -20.56x | -22.39x | -11.10x | -2575.33x | - | - | - | - | -26.63x |
FCF Conversion | 0.83x | 0.87x | 0.80x | 5.80x | 0.85x | 0.65x | 0.89x | 0.41x | 2.15x | 0.80x |
Related:CRVS Dividend History·CRVS Revenue History·CRVS Price History·CRVS P/E History·CRVS Financial Ratios·CRVS Institutional Holders
CRVS SEC Filings & Documents
Corvus Pharmaceuticals, Inc. (CRVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRVS Frequently Asked Questions
Corvus Pharmaceuticals, Inc. (CRVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Corvus Pharmaceuticals, Inc. (CRVS) grew revenue by 0.0% over the past year. Growth has been modest.
Corvus Pharmaceuticals, Inc. (CRVS) reported a net loss of $44.2M for fiscal year 2025.
Dividend & Returns
Corvus Pharmaceuticals, Inc. (CRVS) has a return on equity (ROE) of -32.6%. Negative ROE indicates the company is unprofitable.
Corvus Pharmaceuticals, Inc. (CRVS) had negative free cash flow of $35.1M in fiscal year 2025, likely due to heavy capital investments.